15 September 2017

Consilium Strategic Communications clients win multiple awards at the Biotech and Money Awards 2017


London, 15 September 2017, Consilium Strategic Communications, a global leader in strategic healthcare communications, would like to congratulate all the winners at last night’s Biotech and Money Awards 2017.


Consilium is delighted to announce that a number of its clients have won awards at the Biotech and Money Awards 2017.

“The Biotech and Money Awards recognise excellence in science, funding and investment and leadership in UK life sciences, giving executives the opportunity to celebrate their achievements among their peers. “We are thrilled so many Consilium clients received recognition last night across multiple categories. To collect so many awards is a testament to the quality of our clients, their hard work and the advice and support we at Consilium offer to each company we represent.”

Mary-Jane Elliott

Managing Partner of Consilium Strategic Communications

Consilium clients who won awards include:


UK Public Life Science Company of 2017 – Horizon Discovery

UK Public Finance Raise of 2017 – Oxford BioMedica

UK Life Science CEO of 2017 – Dr Darrin M. Disley, Horizon Discovery

Start-Up Life Science Company of 2017 – Artios Pharma

UK Private Finance Raise of 2017 – Artios Pharma

Life Science Communications Strategy of the Year – Horizon Discovery and Consilium Strategic Communications



For more information please contact:


Consilium Strategic Communications


Mary-Jane Elliott / Amber Fennell


Tel: +44(0)20 3709 5700






Follow us: @consiliumhc


About Consilium Strategic Communications


Consilium Strategic Communications is a global leader in strategic healthcare communications advisory with offices in London and across the US. Consilium's highly-skilled team provides strategic, long-term advice to healthcare companies, Boards, senior decision makers and executives on critical communications programmes and stakeholder challenges. The Company has established deep knowledge across all areas of the global healthcare sector through broad experience in representing international clients spanning the Fortune 500, FTSE100, FTSEurofirst 300 and FTSE250, through to discrete specialist reputation management projects.

Back to previous page